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The traditional view of p53 activation includes three steps—p53 stabilization, DNA binding, and 
transcriptional activation. However, recent studies indicate that each step of p53 activation is 
more complex than originally anticipated. Moreover, both genetic studies in mice and in vitro 
studies with purified components suggest that the classical model may not be sufficient to explain 
all aspects of p53 activation in vivo. To reconcile these differences, we propose that antirepres-
sion, the release of p53 from repression by factors such as Mdm2 and MdmX, is a key step in the 
physiological activation of p53.Introduction
The year 2009 celebrates the 30th anniversary of the discov-
ery of p53 (Lane and Crawford, 1979; Linzer and Levine, 1979; 
DeLeo et al., 1979) and the 20th anniversary of its characteriza-
tion as a tumor suppressor (Baker et al., 1989; Finlay et al., 
1989). Mutations that perturb p53 function, often in its DNA-
binding domain, or disruptions to p53’s upstream or down-
stream regulatory network, have been found in more than half 
of all cancer cases and are present in cancer-prone families 
with Li-Fraumeni syndrome (Hainaut and Hollstein, 2000; 
Vogelstein et al., 2000).
p53 has been called a “cellular gatekeeper” (Levine, 1997) or 
“the guardian of the genome” (Lane, 1992) because of its cen-
tral role in coordinating the cellular responses to a broad range 
of cellular stress factors. p53 functions as a node for organizing 
whether the cell responds to various types and levels of stress 
with apoptosis, cell cycle arrest, senescence, DNA repair, cell 
metabolism, or autophagy. p53-controlled transactivation of 
target genes is an essential feature of each stress response 
pathway, although some effects of p53 may be independent of 
transcription (Vogelstein et al., 2000; Vousden and Lane, 2007; 
Marchenko and Moll, 2007). As a transcription factor that both 
activates and represses a broad range of target genes, p53 
demands an exquisitely complicated network to control and 
fine-tune responses to the various stress signals encountered 
by cells (Brooks and Gu, 2003; Laptenko and Prives, 2006). 
p53 is regulated by an array of posttranslational modifica-
tions both during normal homeostasis and in stress-induced 
responses. More than 36 different amino acids within p53 have 
been shown to be modified in various biochemical and cell cul-
ture studies (Figure 1) (Kruse and Gu, 2008b).
Classical models for the activation of p53 focus on three sim-
ple and rate-limiting steps: p53 stabilization induced by ATM/
ATR-mediated phosphorylation, sequence-specific DNA bind-
ing, and target gene activation by interacting with the general 
transcriptional machinery (Figure 2). However, as discussed in 
this review, the diversity and number of modifications, as well 
as recent studies from knockin mutant mice, suggest a certain degree of redundancy among these modifications. These find-
ings challenge the importance of a number of the traditional 
regulatory events of p53 activation (Iwakuma and Lozano, 
2007; Marine et al., 2006; Wahl, 2006; Brooks and Gu, 2006) 
and raise questions that cannot be sufficiently explained by 
the three steps of the classical model. What is the exact mech-
anism controlling p53 stabilization in vivo? Does p53 require 
additional activation to induce binding to DNA or is p53 already 
bound to DNA yet unable to induce transactivation in vivo? 
Does p53 require activation, or is it intrinsically active in vivo? 
How are decisions of cell fate controlled in vivo in response to 
different types and severities of stress? To incorporate recent 
findings, we revisit the different stages of p53 activation here. 
We propose that antirepression is a key mechanism for p53 
regulation in vivo. Introducing this step for p53 activation into 
existing models may help to explain the events leading to p53 
activation in vivo.
Mechanisms of p53 Stabilization
The Classical Model
Phosphorylation of p53 is classically regarded as the first cru-
cial step of p53 stabilization. p53 can be modified by phospho-
rylation by a broad range of kinases, including ATM/ATR/DNA-
PK, and Chk1/Chk2 (see Figure 1). Phosphorylation of serine 
residues within the N-terminal p53 transactivation domain was 
among the first posttranslational modifications of p53 identi-
fied and has been extensively investigated in in vitro biochemi-
cal assays, in tissue culture studies, and recently by using site-
specific knockin animals. N-terminal phosphorylation at Ser15 
(mouse Ser18) and Ser20 (mouse Ser23) have been generally 
thought to stabilize p53 by inhibiting the interaction between 
p53 and Mdm2 (Figure 2). Ser15 and Ser20 are phosphorylated 
after DNA damage and other types of stress by ATM, ATR, 
DNA-PK, Chk1, and Chk2 (Appella and Anderson, 2001; Shieh 
et al., 1997; Shieh et al., 2000). Although it remains unresolved 
which of the different kinases perform the phosphorylation of 
these N-terminal regulatory sites in response to the varying 
stress signals, and to which extent N-terminal phosphoryla-Cell 137, May 15, 2009 ©2009 Elsevier Inc. 609
Figure 1. Overview of p53 Posttranslational Modifications
More than 36 amino acids of p53 are reported to be modified. The major sites of p53 phosphorylation (P), ubiquitination (Ub), and acetylation (Ac) are shown 
with the corresponding major modifying enzymes and signals. Furthermore, additional phosphorylation and acetylation sites, as well as major sites of methyla-
tion (Me), sumoylation (S), neddylation (N8), glycosylation (O-Glc), and ribosylation (ADP), are indicated.tion affects the p53-MDM2 interaction, the general consensus 
remains that their phosphorylation occurs rapidly in response 
to various stress stimuli to activate p53.
However, knockin mouse models with individual mutations 
of these N-terminal sites question the importance of the indi-
vidual modifications in p53 stabilization in vivo. Studies with 
a Ser18Ala point mutant knockin mouse (S18A) indicate that 
at least some of the in vitro effects may not translate directly 
to a whole organism (Chao et al., 2003; Sluss et al., 2004). 
Although some mild effects on p53 levels in the knockin cells 
are observed, stress-induced p53 stabilization is comparable 
in thymocytes, splenocytes, and fibroblasts derived from wild-
type and mutant knockin mice. The consistency in p53 levels in 
these studies argues against a dominant role for S18 phospho-
rylation in the regulation of the p53-MDM2 interaction in vivo, 
as a failure to phosphorylate S18 should promote this inter-
action and therefore induce p53 ubiquitination and degrada-
tion. Similar results are obtained with p53-serine 23 to alanine 
(S23A) point mutant knockin animals (MacPherson et al., 2004; 
Wu et al., 2002). Interestingly, more severe defects on both the 
levels and function of p53 were found in the S18/23A double-
mutant mice, lending support to the physiological importance 
of these two key phosphorylation sites (Chao et al., 2006a). 
Nevertheless, these defects are limited to certain tissues and 
mostly for DNA-damage-induced apoptosis. For example, no 
obvious effects were observed in mouse embryonic fibroblasts 
or other tissues from the S18/23A double-mutant mice. These 
results suggest that under specific conditions, p53 phospho-
rylation is required for p53 stabilization. However, the fact that 
no differences in stability were observed in other tissues or in 
embryonic fibroblasts argues that phosphorylation may not be 
a universal requirement for p53 stabilization. Indeed, results 610 Cell 137, May 15, 2009 ©2009 Elsevier Inc.from a wide range of studies have established that p53 can be 
activated regardless of its phosphorylation status (Ashcroft et 
al., 1999; 2000; Blattner et al., 1999; Wu et al., 2002). Together, 
these genetic and biochemical studies emphasize the notion 
that p53 stabilization in vivo requires a far more sophisticated 
regulatory network than can be provided by p53 phosphoryla-
tion alone.
The Many Layers of Mdm2 Regulation
The tight control of cellular p53 levels is primarily achieved 
through its ubiquitin-mediated proteasomal degradation 
(Brooks and Gu, 2006; Michael and Oren, 2003). Three inde-
pendent studies identified the mouse double minute protein 2 
(Mdm2) as the principal endogenous E3-ligase with high speci-
ficity for p53 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et 
al., 1997). Interestingly, although the level of p53 is elevated in 
the absence of Mdm2, p53 is still degraded in the cells of Mdm2 
null mice (Ringshausen et al., 2006), suggesting the existence 
of alternative, Mdm2-independent pathways for p53 degrada-
tion in vivo. Indeed, the recently discovered E3-ligases COP1 
(Dornan et al., 2004), Pirh2 (Leng et al., 2003), Arf-BP1 (Chen 
et al., 2005), and others have clearly been shown to contribute 
to the efficient control of p53 levels in tissue culture and in in 
vitro biochemical experiments. Nevertheless, the precise roles 
of Mdm2-independent degradation in stress-induced p53 sta-
bilization remain to be elucidated.
There are multiple layers of regulation that connect Mdm2 
function with p53 stability during stress responses. A promi-
nent physiological regulator of Mdm2 is the tumor suppressor 
ARF (Lowe and Sherr 2003). ARF interferes with the Mdm2-p53 
interaction, thereby acting to stabilize and activate p53. The 
low steady-state levels of ARF in normal cells are dramatically 
induced upon oncogenic stress, which suppresses abnormal 
cell proliferation by triggering p53-dependent growth arrest 
or apoptosis (Sherr, 2006). Interestingly, the mechanisms by 
which ARF activates p53 function are complex. On one hand, 
ARF is predominately a nucleolar protein. Elegant work has 
shown that ARF can stabilize nucleoplasmic p53 by binding 
Mdm2 and sequestering it in the nucleolus (Weber et al., 1999). 
Yet, equally convincing studies have also shown that nucleo-
plasmic forms of ARF activate p53 by directly inhibiting the 
ubiquitin ligase activity of Mdm2 (Llanos et al., 2001; Honda 
and Yasuda., 1999). Moreover, in addition to suppressing 
Mdm2-mediated effects on p53, ARF may modulate the activ-
ity of other E3 ligases such as ARF-BP1, and our recent stud-
ies demonstrate that the ARF/ARF-BP1 interaction is involved 
in both p53-dependent and p53-independent functions of 
ARF (Chen et al., 2005). Thus, although the precise molecu-
lar mechanisms by which ARF mediates these activities need 
further elucidation, it is clear that ARF has an essential role in 
p53 regulation.
The other prominent regulator of Mdm2 activity is MdmX 
(also known as Mdm4). Like Mdm2, MdmX is a critical nega-
tive regulator of p53 (Marine and Jochemsen, 2005). The 
direct roles played by MdmX on p53 activity are discussed 
in more detail below; here, we focus on the ability of MdmX 
to regulate the function of Mdm2. Mdm2 and MdmX interact 
with each other via their C-terminal RING domains. Interest-
ingly, MdmX stabilizes both Mdm2 and p53, yet MdmX also 
promotes the E3-ligase activity of Mdm2 (Linares et al., 2003; 
Poyurovsky et al., 2007; Uldrijan et al., 2007). The ability of 
MdmX to promote Mdm2 function, as well as its own direct 
impact on p53, suggests that MdmX, like Mdm2, may be a 
potential therapeutic target for regulating p53 activity (Shan-
gary and Wang, 2009). In addition, the transcription factor 
YY1 and the ribosomal proteins L5, L11, and L23 interact with 
Mdm2 and regulate its function. YY1 promotes the ubiquitina-
tion of p53 in vivo and in vitro by strengthening the interaction 
between p53 and Mdm2 (Sui et al., 2004). Conversely, binding 
of the ribosomal proteins L5, L11, and L23 to Mdm2 inhibits 
Mdm2 function and plays a crucial role in p53 activation upon 
ribosomal stress (Dai et al., 2004; Lohrum et al., 2003; Zhang 
et al., 2003).
The complexity of the regulation of p53 stability through 
Mdm2 becomes even more apparent when considering the 
activity of the deubiquitinating enzyme HAUSP. Mdm2 is an 
unstable protein, primarily due to autoubiquitination or its ubiq-
uitination by undefined E3 ligases (Fang et al., 2000; Stommel 
and Wahl, 2004; Itahana et al., 2007). HAUSP not only deu-
biquitinates p53 (Li et al., 2002a), but also Mdm2 (Cummins 
et al., 2004; Li et al., 2004). The protein DAXX is an important 
component of this multiprotein complex that regulates HAUSP-
mediated deubiquitination of Mdm2 (Tang et al., 2006a), and 
recent work now shows that the assembly of this complex is 
in part regulated by the protein RASSF1A (Song et al., 2008). 
RASSF1A disrupts the interaction between Mdm2, DAXX, and 
HAUSP, thereby promoting Mdm2 ubiquitination, and conse-
quently resulting in p53 stabilization. As this example dem-
onstrates, an ever growing number of proteins continue to be 
defined that affect the levels or activities of Mdm2 and thereby 
influence p53 levels.Mdm2 is also subject to regulation by phosphorylation 
and acetylation. Various phosphorylation sites have been 
described, and depending on the site and the modifying 
kinase, these modifications can inhibit or activate the activity 
of Mdm2 (reviewed in Meulmeester et al., 2005). ATM and c-Abl 
inhibit Mdm2 activity via the phosphorylation of Ser395 (S395) 
and Tyr394, respectively, whereas phosphorylation of Ser166 
and Ser186 promote its E3-ligase activity (Meek, 2004; Mayo 
and Donner, 2002). Conversely, dephosphorylation of Mdm2 
by WIP1 stabilizes Mdm2 and facilitates p53 ubiquitination and 
degradation (Lu et al., 2007). Mdm2 activity is also inhibited 
by CBP/p300-mediated acetylation, resulting in increased p53 
levels (Wang et al., 2004). This provides an interesting level of 
coordinated p53 regulation, as acetylation of the p53 C termi-
nus also blocks at least some of the major p53 ubiquitination 
sites used by Mdm2 for p53 degradation. The six C-terminal 
lysines of p53 are acetylated by CBP/p300 (Gu and Roeder, 
1997). Ubiquitination and acetylation are mutually exclusive 
modifications, and competition between these modifications is 
thought to affect p53 stability. p53 acetylation levels are mark-
edly enhanced in response to stress, promoting p53 stabili-
zation and activation (Brooks and Gu, 2003; Luo et al., 2001; 
Sakaguchi et al., 1998). Purified acetylated p53 cannot be ubiq-
uitinated by Mdm2 in vitro, and ubiquitination is significantly 
reduced upon induction of acetylation (Ito et al., 2001; Li et al., 
2002b). More recent work has shown that the acetylation of 
eight different lysine residues on p53 prevents the interaction 
between p53 and Mdm2 (Tang et al., 2008). Therefore, both 
phosphorylation and acetylation of p53 can inhibit the Mdm-
-p53 interaction, suggesting a critical role of posttranslational 
modifications in affecting the p53/Mdm2 feedback loop.
Due to the importance of the Mdm2-p53 interaction, inhibi-
tion of this event with small molecules is regarded as having 
therapeutic potential. A number of different strategies have 
been employed to screen for and develop small molecules that 
bind specifically to the N-terminal region of Mdm2 that inter-
acts with p53 (Shangary and Wang, 2009). The most promising 
candidates described so far have been Nutlin-3A (Vassilev et 
al., 2004) and MI-219 (Shangary et al., 2008), and analogs of 
these lead compounds are being developed or have already 
entered preclinical development or early clinical trials. As 
expected, inhibition of the Mdm2-p53 interactions by small 
molecules results in increased p53 levels. The significance of 
controlling the ubiquitin ligase activity of Mdm2 is further bol-
stered by work studying the effects of a site-specific (C462A) 
knockin mutation of Mdm2 (Itahana et al., 2007). Notably, 
HLI98, a promising inhibitor of Mdm2 E3 ligase activity, also 
activates p53 (Yang et al., 2005). Nevertheless, the outcome 
of raising p53 levels and subsequent p53-mediated apoptosis 
is very dependent on the cell or tissue type. It will be of great 
interest to determine whether these compounds when used in 
combination therapies might selectively target cancer cells in 
the clinic.
The six C-terminal lysines of p53 are the predominant sites 
for Mdm2-mediated ubiquitination (Lohrum et al., 2001) (Figure 
1). Although the in vitro data certainly demonstrate the impor-
tance of the six C-terminal lysines of p53 for Mdm2-mediated 
ubiquitination, knockin studies in which the equivalent lysines Cell 137, May 15, 2009 ©2009 Elsevier Inc. 611
are mutated in analogous fashion to arginines (p53-6KR 
knockin mice) do not dramatically alter p53 protein levels 
(Feng et al., 2005; Krummel et al., 2005). Analysis of p53 pro-
tein stability in embryonic stem cells, embryonic fibroblasts, 
and thymocytes derived from p53-6KR mutant knockin ani-
mals reveals normal p53 stabilization both before and after 
DNA damage (Feng et al., 2005). Furthermore, the half-life of 
an analogous p53-7KR mutant (a mouse p53 construct with 
the seven C-terminal lysines mutated) showed no difference 
when compared to wild-type p53 in embryonic fibroblasts and 
thymocytes derived from p53-7KR knockin mice (Krummel et 
al., 2005). Together, these two studies support the theory that 
the C-terminal lysines are not essential for efficient p53 degra-
dation in vivo and that additional E3-ligases, as well as ubiq-
uitination of additional p53 lysines, are required for effective 
p53 regulation. Recent in vitro data suggest that lysine resi-
dues located in the DNA-binding domain and in the N-terminal 
region may be ubiquitinated (Chan et al., 2006). Thus, the sites 
of Mdm2-mediated ubiquitination are not as specific as origi-
nally anticipated. It is very likely that the C terminus of human 
p53 is preferentially targeted by Mdm2 for ubiquitination, but 
Mdm2 is still able to degrade p53 in vivo in the absence of 
these sites.
The levels of nuclear p53 are also modulated by degrada-
tion-independent ubiquitination. Mdm2-mediated p53 monou-
biquitination, occurring when Mdm2 activity levels are low, 
promotes p53 nuclear export and accumulation of cytoplas-
mic p53 (Lohrum et al., 2001; Li et al., 2003; Marchenko et al., 
2007). Although originally thought of as a passive way to block 
the nuclear function of p53, accumulating evidence suggests 
that cytoplasmic localization of p53 plays an active role in p53-
mediated functions such as apoptosis and autophagy. Once in 
the cytoplasm, p53 can localize to the mitochondria, where it 
induces apoptosis (Marchenko and Moll, 2007). p53 interacts 
with antiapoptotic members of the Bcl family such as Bcl-XL 
Figure 2. Classical Model of p53 Activation
The classical model for p53 activation generally consists of three sequential 
activating steps: (1) stress-induced stabilization mediated by phosphorylation 
(P), (2) DNA binding, and (3) recruitment of the general transcriptional machin-
ery. During normal homeostasis, p53 is degraded after Mdm2-mediated ubiq-
uitination (left), while stress signal-induced p53 phosphorylation by ATM, ATR, 
and other kinases stabilizes p53 and promotes DNA binding. DNA-bound p53 
then recruits the transcriptional machinery to activate transcription of p53 tar-
get genes.612 Cell 137, May 15, 2009 ©2009 Elsevier Inc.and Bcl-2 at the outer mitochondrial membrane to promote 
the oligomerization of the proapoptotic factors Bak and Bax. 
These in turn drive the formation of pores in the mitochondrial 
membrane, resulting in the release of cytochrome c and other 
apoptotic activators from the mitochondria (Chipuk et al., 2004; 
Mihara et al., 2003; Tomita et al., 2006). Alternatively, p53 can 
directly interact with Bak, releasing Bak from its inhibitory inter-
action with Mcl1 (Leu et al., 2004). Further evidence shows that 
changes in subcellular localization of p53 can have profound 
effects on the cell. Recently, cytoplasmic p53 has been shown 
to regulate autophagy (Tasdemir et al., 2008). An additional fac-
tor that regulates p53 localization is MSL2, another E3-ligase 
for p53, which can promote its cytoplasmic localization inde-
pendent of Mdm2 (Kruse and Gu, 2008a). Significantly, this 
RING-E3 does not affect p53 levels or Mdm2 mediated-p53 
monoubiquitination, and targets different lysines (K351, K357) 
for ubiquitination than Mdm2 (Figure 1). It will be interesting 
to determine whether MSL2 regulates apoptosis or other roles 
ascribed to cytoplasmic p53.
Together, the studies using knockin mice with mutations in 
p53’s phosphorylation sites and C-terminal lysine residues 
indicate that p53 stabilization in vivo involves many different 
mechanisms. None of the sites tested is able to recapitulate 
in vivo the dramatic effects on p53 stabilization observed in in 
vitro biochemical and tissue culture studies. Overall, the model 
for p53 stabilization in vivo has shifted from a primary empha-
sis on p53 phosphorylation to a greater appreciation for the 
multiple layers of Mdm2 regulation. However, it remains incom-
pletely understood how p53 is stabilized in vivo in different tis-
sues and in response to different stress signals.
Sequence-Specific DNA Binding
An early breakthrough for the p53 field was the discovery that 
p53 is a sequence-specific DNA-binding protein (Bargonetti et 
al., 1991; Kern et al., 1991). The DNA consensus sequence of 
p53 response elements was subsequently identified by in vitro 
assays (El-Deiry et al., 1992) and has been recently refined by 
chromatin immunoprecipitation (ChIP) sequencing in human 
cells (Wei et al., 2006). The consensus sequence contains two 
inverted pentameric sequences with the pattern 5′-RRRC(A/
T)|(A/T)GYYY-3′. The importance of sequence-specific DNA 
binding is underscored by the fact that the vast majority of tumor-
associated p53 mutations occur within its DNA-binding domain 
(Hainaut and Hollstein, 2000), which consists of a beta sand-
wich with a series of loops and short helices (Cho et al., 1994). 
Transactivation requires p53 to interact with promoter regions 
of p53 target genes. In the classical model for p53 activation, 
the second canonical step is the binding of stress-activated and 
posttranslationally modified p53 to specific response elements 
in the promoters of target genes (Figure 2). As discussed below, 
it is unclear whether DNA binding by p53 is dependent on stress 
signals or other modes of regulation. Early studies focused on 
the ability of p53 to bind DNA in a sequence-specific manner. 
DNA binding was thought to occur via the conserved central 
core domain, whereas the C-terminal region was thought to 
act as a negative modulator that had to be modified to allow 
sequence-specific DNA binding. Phosphorylation, ubiquitina-
tion, methylation, sumoylation, neddylation, and acetylation all 
target and modify the C-terminal region of p53, thereby affect-
ing the ability of p53 to bind DNA (Appella and Anderson, 2001; 
Brooks and Gu, 2003). In addition to affecting DNA binding via 
the core domain, these modifications may affect C terminus-
mediated DNA binding, direct other regulatory events such as 
cofactor recruitment, and provide sequence specificity.
The ability of stress-induced, allosteric activation of unmodi-
fied p53 to bind sequence specific DNA (Hupp et al., 1992) has 
recently been questioned by a variety of studies. Experiments 
using larger DNA molecules or chromatin as targets demon-
strate that activation of p53 is not required for p53 to bind to 
DNA (Cain et al., 2000; Kim et al., 1999). Furthermore, analysis 
of wild-type and mutant p53 variants using nuclear magnetic 
resonance show that presumed latent and active p53 have an 
extremely similar molecular structures and that the C-terminal 
region does not interact with the central DNA-binding region 
(Ayed et al., 2001). It is currently believed that both the core 
DNA-binding domain and the C-terminal domain of p53 pos-
sess DNA-binding activities, with the former primarily provid-
ing sequence specificity whereas the latter recognizes struc-
tural features of target DNA.
In light of its ability to bind DNA both based on sequence 
specificity and on DNA structure and topology, the question 
of whether stress is required to induce DNA binding of p53 
becomes even more intriguing. A number of recent studies now 
provide additional evidence that a significant portion of p53 is 
bound to DNA in unstressed cells. An unbiased global ChIP 
assay demonstrates that the C-terminal domain facilitates p53 
binding to genomic DNA, and only 5% of p53-bound genomic 
sequence isolated by ChIP contains the p53 consensus sites (Liu 
et al., 2004). Furthermore, a microarray analysis of p53 binding 
to genomic DNA also shows that only 2% of p53 binding events 
are associated with p53 consensus sites (Cawley et al., 2004). In 
addition to this nonspecific binding to DNA, ChIP assays show 
that p53 is present at promoters of its transcriptional targets 
during normal homeostasis (Kaeser and Iggo, 2002; Szak et al., 
2001). Quantitative ChIP assays demonstrate that p53 is present 
at the promoters of the p21 and Mdm2 genes from wild-type, 
unstressed p53 cells. These findings provide further support for 
a model in which p53 is capable of binding DNA in unstressed 
cells but remains inactive probably because of repression by 
Mdm2 and MdmX. 
Overall, there is no doubt that the binding of p53 to DNA is 
essential for p53 function, yet it may not be a rate-limiting step in 
the p53 response as originally thought (Hupp et al., 1992). DNA 
binding received tremendous attention early on, in part due to 
the poor DNA binding activity of p53 in vitro and the known 
tumor-derived mutants that affect DNA binding. However, recent 
work has shown that in many cases p53 is already bound to the 
p53 target promoters without activating transcription, although 
it remains possible that acetylation is important for enhance-
ment of DNA binding on some specific p53 proapoptotic targets 
(Sykes et al., 2006).
Insights into Promoter-Specific Activation
Early studies suggest that p53 promotes transcription activa-
tion by simply interacting with general transcription factors 
such as TFIID/TAFs or components of SRB/mediator com-plexes (Thut et al., 1995; Gu et al., 1999). This simple model 
for transcriptional activation belies the complexity of achieving 
promoter specificity. In broad terms, promoter specific trans-
activation could be achieved by the interaction of p53 with 
specific repressors and activators. The interaction of repres-
sors and activations might be regulated by the posttransla-
tional modification of p53, or interacting proteins might pro-
mote changes in p53 posttranslational modification to achieve 
promoter-specific transactivation. Although there are many 
proteins reported to bind and regulate p53, very few have been 
shown to be physically recruited to the promoters of p53 tar-
gets, and genetic evidence identifying them as bona fide regu-
lators of p53 is typically lacking. To provide a structure and an 
overview for this very complex topic, we discuss the roles of 
p53 repressors and activators and the impact of various p53 
modifications in detail below.
p53 Repression by MdmX and Mdm2
Mdm2 and MdmX are structurally related proteins, and physi-
ological levels of both proteins are required in a nonredundant 
manner to balance p53 activity during embryonic development 
(Marine et al., 2006). The functions of p53 are downregulated 
by the Mdm2 oncoprotein, at least in part by ubiquitin-medi-
ated proteolysis (Brooks and Gu, 2006). The central role of 
Mdm2 in this process is best illustrated by studies carried out 
in mice, where inactivation of p53 was shown to completely 
rescue the embryonic lethality caused by loss of Mdm2 func-
tion (Jones et al., 1995; Montes de Oca Luna et al., 1995). Nota-
bly, MdmX knockout mice die despite having functional Mdm2, 
and this lethality is also rescued by inactivation of p53 (Parant 
et al., 2001; Migliorini et al., 2002). Thus, MdmX is as critical as 
Mdm2 in repressing p53 function. In addition to promoting p53 
degradation, accumulating evidence indicates that Mdm2 and 
MdmX form a protein complex with p53 on the promoters of 
specific p53 target genes (Minsky and Oren, 2004; Ohkubo et 
al., 2006; Tang et al., 2008).
Initial studies indicate that MdmX represses p53-medi-
ated transcriptional activation (Marine and Jochemsen, 
2005). Despite its sequence homology with Mdm2 and the 
presence of a RING domain, MdmX does not have intrinsic 
E3-ligase activity for p53 but instead inhibits p53-induced 
transcription. The interplay between p53, Mdm2, and MdmX 
is an extremely interesting topic, and new studies with 
mutant mice highlight their intricate relationship (Iwakuma 
and Lozano, 2007; Marine et al., 2006; Wahl, 2006), arguing 
that the major role of MdmX lies in its ability to repress but 
not degrade p53. Mdm2 and MdmX can both be recruited 
to p53 promoter regions and act via a multitude of mecha-
nisms to repress transcription of p53 target genes (Tang et 
al., 2008). The various results from animal studies, together 
with in vitro and tissue culture data, have led to models 
that describe the distinct yet combinatorial roles played by 
these two negative regulators of p53 (Marine et al., 2006; 
Wahl, 2006). Mdm2 and MdmX may determine whether a cell 
responds to p53 activation with growth arrest or apoptosis, 
but the molecular mechanism of these differential effects 
remains unknown (Barboza et al., 2008). It is possible that 
Mdm2 and MdmX are recruited by p53 to different target 
promoters to execute distinct functions.Cell 137, May 15, 2009 ©2009 Elsevier Inc. 613
p53 Acetylation and Promoter-Specific Activation
Histone acetyltransferases (HATs) provide an important layer 
of p53 regulation, particularly in transcription (Brooks and Gu, 
2003). The covalent linkage of an acetyl group to a lysine resi-
due was first discovered on histones, and histone acetylation 
is now known to have a major impact on transcriptional regula-
tion (Jenuwein and Allis, 2001). However, histones are not the 
only proteins that can be acetylated; p53 was the first nonhis-
tone substrate shown to be functionally regulated by acetyla-
tion and deacetylation (Gu and Roeder, 1997; Luo et al., 2000). 
p53 is acetylated by the histone acetyltransferase CBP/p300, 
and CBP/p300 mutations are found in several types of human 
tumors (Goodman and Smolik, 2000; Iyer et al., 2004). p53 
acetylation is critically important both for the efficient recruit-
ment of cofactors and for the activation of p53 target genes 
in vivo. Once localized at promoter regions, CBP/p300 can 
enhance transcription by acetylating histones in the vicinity of 
target genes, thereby establishing a more accessible chroma-
tin conformation, and by bridging transcription factors to the 
pol II holoenzyme (Goodman and Smolik, 2000). In addition, 
the acetyltransferases Tip60 and hMof are cofactors that can 
be recruited by p53 and are able to acetylate p53 as well as 
histones (Tang et al., 2006b; Sykes et al., 2006). The acetyl-
transferase activity of Tip60 is implicated in both DNA repair 
and apoptosis, but, most significantly, evidence suggests that 
Tip60 is a p53 activator by a large-scale RNA interference 
screen (Berns et al., 2004).
p53 acetylation is elevated in response to stress, and levels 
of acetylation correlate well with p53 activation and stabiliza-
tion (Luo et al., 2000; 2001; Vaziri et al., 2001; Ito et al., 2001; 
Knights et al., 2006). The transcription phenotypes described 
for the C-terminal acetylation-deficient p53-6KR knockin mice 
show that p53-dependent gene expression in embryonic stem 
cells and thymocytes is impaired in a promoter-specific man-
ner after DNA damage. This finding supports the theory that 
C-terminal acetylation helps to activate p53 dependent trans-
activation after DNA damage (Feng et al., 2005). However, the 
transcription profiles in cells from the 6KR knockin mice show 
some cell type specificity, with the most dramatic differences 
observed in embryonic stem cells, a more selective defect in 
thymocytes, and no significant differences in embryonic fibro-
blasts. Similarly, embryonic fibroblasts generated from the 
p53-7KR knockin mice did not show substantial differences 
in p53-mediated cell cycle control or apoptosis (Krummel et 
al., 2005). Together, these two knockin studies suggest that 
C-terminal acetylation shows some cell type-specific regu-
latory effects, but does not have a major general impact on 
apoptosis or cell cycle control. In addition to CBP/p300, p300/
CBP associated factor (PCAF) is another transcriptional coact-
ivator of p53, which acetylates p53 at lysine K320 (K317 in 
mice) (Sakaguchi et al., 1998; Liu et al., 1999). Analysis of K317 
acetylation in a mouse model shows that a K317R mutant p53 
protein is stabilized and accumulates at a rate comparable to 
wild-type p53 in embryonic fibroblasts and thymocytes (Chao 
et al., 2006b). Although the expression profile of p53 target 
genes is largely normal in K317R mouse embryonic fibroblasts, 
the authors surprisingly find an increase in the expression of 
proapoptotic genes in thymocytes. There is also an increase in 
the apoptotic response upon irradiation in thymocytes and epi-
thelial cells from the small intestine, indicating that the effects 
of K320 acetylation by PCAF are far more complicated than 
originally anticipated.
Although the C-terminal lysine mutant knockin animal mod-
els raise some concerns over the importance of C-terminal 
acetylation, recent studies show that p53 acetylation is not 
limited to this domain (Sykes et al., 2006; Tang et al., 2006b). 
Both studies show that lysine K120 is acetylated, providing an 
example of transcriptional regulation mediated by acetylation 
that requires the DNA-binding core domain. In contrast to other 
sites of p53 modification, K120 is conserved in all species that 
contain functional p53 genes, implying that this modification 
may have an evolutionarily conserved role. K120 is acetylated 
by hMOF and TIP60, acetyltransferases of the MYST family that 
share no homology with the CBP/p300 or PCAF acetyltrans-
ferases. K120 acetylation is essential for p53-mediated activa-
tion of the proapoptotic target genes puma and bax, whereas 
expression of p21 and Mdm2 are not affected. Furthermore, 
K120 modification affects neither p53 stability nor p53-DNA 
Figure 3. p53 Acetylation and Target Gene 
Regulation
Upon stress-induced p53 activation, different sets 
of p53 target genes have different requirements for 
p53 posttranslational modifications.
(A) A number of promoters can be activated by un-
acetylated p53. This class of p53 target genes pro-
tects cells from excessive p53 activation. These 
target genes include Mdm2, Pirh2, and others.
(B) The activation of genes involved in DNA re-
pair and cell cycle control requires recruitment 
of specific histone acetyltransferases (HATs) and 
partial acetylation (Ac), acting at least in part by 
anti repression.
(C) Full acetylation of p53 is required for the acti-
vation of proapoptotic genes. Activation of these 
targets induces a program to ensure efficient 
apoptosis.614 Cell 137, May 15, 2009 ©2009 Elsevier Inc.
binding. K120 acetylation occurs after DNA damage, as well 
as after activation of the p19ARF oncogenic stress pathway 
(Mellert et al., 2007; Tang et al., 2006b). K164 is another newly 
identified site of acetylation by CBP/p300. Like K120, K164 is 
located within the DNA-binding domain (Tang et al., 2008), and 
both residues are recurrent sites for p53 mutation in human 
cancer (Hainaut and Hollstein, 2000). Simultaneous loss of 
acetylation at K120, K164, and the six C-terminal lysines com-
pletely abolishes the ability of p53 to activate p21 and sup-
press cell cycle progression (Tang et al., 2008). Interestingly, 
separate acetylation defects at K120, K164, or the 6KR sites 
can be compensated by acetylation of the other sites, enabling 
p53-mediated transcription of p21. Importantly, an acetylation-
defective p53-8KR mutant retains the ability to function as a 
DNA-binding transcription factor and induces the p53-Mdm2 
feedback loop, establishing promoter specificity for this regu-
latory event. The complete inability of the p53-8KR mutants to 
induce cell cycle and apoptotic regulators demonstrates that 
acetylation is absolutely required for key aspects of p53-medi-
ated tumor suppression. Both K120 and K164 residues, as well 
as the majority of the p53 core domain, are highly conserved, 
and it will be of great interest to see what effect a p53 K120R or 
K164R mutation would have in a knockin animal model.
The functional consequences of p53 acetylation suggest that 
the timing of acetylation of the different p53 regions may be 
important for accurate p53 regulation and cell fate determina-
tion. It is very likely that distinct mechanisms activate different 
types of p53 targets during the course of the stress response. 
For each p53-dependent stress response, at least three different 
classes of target genes can be turned on by p53 to execute p53-
mediated function at different levels (Figure 3). The first class of 
p53 target genes protects cells from excessive p53 activation; 
these include Mdm2, Pirh2, and others. Given that activated p53 
is potentially dangerous to cell viability, the feedback mediated 
by Mdm2 is probably an early step in the p53-mediated stress 
response. p53 modification (at least, in the case of acetylation) 
and coactivator recruitment (e.g., Tip60) are not required for this 
step (Tang et al., 2006b, 2008). The second class of p53 target 
genes induces growth arrest, and these genes are particularly 
important for cells to initiate productive DNA repair. The most 
important target of this class is p21. p53-dependent recruit-
ment of coactivators such as CBP/p300 and Tip60/hMOF is 
absolutely required for p21 activation (Sykes et al., 2006; Tang 
et al., 2006b). Nevertheless, p21 induction is probably redun-
dantly regulated via the modification of p53 at multiple sites. 
Although the complete loss of p21 induction in the absence of 
p53 acetylation in the 8KR mutant cells demonstrates that this 
event is indispensable for p53-mediated growth arrest, a partial 
modification of p53 is sufficient to induce p21 activation (Tang 
et al., 2006b, 2008). The third class of p53 target genes induces 
apoptosis, including PUMA, BAX, NOXA, and others. Given that 
this step initiates an irreversible apoptotic response, the require-
ment for full activation of proapoptotic targets is stringent. For 
example, all the key coactivators have to be recruited to the tar-
get promoters; specific modification (e.g., K120 acetylation) is 
required, and p53 is likely modified at many different sites (Fig-
ure 3). In addition, the corepressors such as Mdm2 and MdmX 
must be completely removed from these target promoters.Conversely, p53 can be deacetylated and acetylation-
dependent upregulation of p53 transactivation can be reversed 
by distinct histone deacetylase (HDAC) complexes containing 
HDAC1 (Luo et al., 2000) or Sir2α/Sirt1 (Luo et al., 2001; Vaziri 
et al., 2001). Deacetylation represses p53-dependent transcrip-
tional activation, apoptosis, and growth arrest. p53 deacetyla-
tion by the HDAC1 complex strongly represses p53 transcrip-
tional activity and modulates growth arrest and apoptosis (Luo 
et al., 2000). Sirt1-mediated p53 deacetylation represses p53-
dependent apoptosis in response to DNA damage and oxida-
tive stress, whereas expression of a Sirt1 dominant-negative 
point mutant increases the sensitivity of cells to stress (Luo et 
al., 2001). This notion is further supported by the observation 
that p53 is hyperacetylated in Sirt1-deficient mice and cells 
from these mice display increased radiation-induced apopto-
sis (Cheng et al., 2003). Sirt1-mediated deacetylation of p53 is 
suppressed by a putative tumor suppressor, DBC-1 (deleted 
in breast cancer gene 1), in human cells (Zhao et al., 2008; 
Kim et al., 2008) and is upregulated by oncogenic viral pro-
tein HPV E7 (Allison et al., 2009). A small molecule, tenovin-6, 
has been recently identified as a potent SIRT1 inhibitor that 
effectively induces p53 activation and cell growth repression in 
cancer cells (Lain et al., 2008). Furthermore, Sirt1 colocalizes 
with p53 in promyelocytic leukemia (PML) nuclear bodies and 
undergoes a conformational change when bound to acetylated 
p53 to antagonize the increase in p53 acetylation induced by 
PML (Pearson et al., 2000). p53 deacetylation may provide a 
quick-acting mechanism to stop p53 function when transcrip-
tional activation of target genes is no longer required. Targeted 
deacetylation occurs very quickly amidst a global equilibrium 
of genomic acetylation and deacetylation. Restoring a steady-
state level of p53 targets after completion of DNA repair is cru-
cial to allow cells to return to normal homeostasis. Deacetyla-
tion could serve as an important step to allow Mdm2-mediated 
p53 degradation, given that acetylation of p53 inhibits p53 
ubiquitination by Mdm2 in vivo and in vitro (Li et al., 2002b).
p53 Transcriptional Activation: Methylation, 
 Sumoylation, and Neddylation
It is not only acetylation and ubiquitination that compete for 
p53’s C-terminal lysines. Methylation, sumoylation, and ned-
dylation all occur at specific sites, and the exact interplay of 
these modifications may contribute to p53 promoter specific-
ity. The many possible variations of these modifications of p53 
may act like a barcode, resulting in specific p53 responses.
To this point, three different methyltransferases have been 
shown to be able to methylate C-terminal lysine residues of 
p53. Set7/9-mediated monomethylation of p53 at lysine K372 
promotes p53 activity, in particular the ability of p53 to trans-
activate p21 (Chuikov et al., 2004). Monomethylation of p53 
at K370 and K382 by Smyd2 and Set8/PR-Set7, respectively, 
represses p53 activity (Huang et al., 2006; Shi et al., 2007). 
Regulated dimethylation of K370 and K382 provides a bind-
ing site for the DNA repair factor 53BP1, and DNA damage 
increases p53 dimethylation and therefore promotes the inter-
action of p53 and 53BP1. Interestingly, the demethylase LSD1 
specifically demethylates K370, thereby removing at least one 
anchoring point for 53BP1 (Huang et al., 2007). Further support 
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the p53 response comes from evidence that both p53 (Jansson 
et al., 2008) and the surrounding histones (An et al., 2004) are 
arginine methylated. An et al. demonstrate that arginine methy-
lation by PRMT1 and acetylation by p300 and CARM1 entails 
both direct modification of p53 as well as the controlled modi-
fication of the surrounding histones to regulate the expression 
of p53 responsive genes. Jansson et al. demonstrate that argi-
nine methylation of p53 by PRMT5 regulates target gene speci-
ficity of p53 by altering promoter binding.
Modification of p53 by the ubiquitin-like modifications SUMO 
and Nedd8 further add to the competition for the C-terminal 
lysines. The exact functional consequences of p53 sumoyla-
tion at K386 are still somewhat unclear. Although some studies 
report that sumoylation promotes p53 transcriptional activity 
(Melchior and Hengst, 2002), others demonstrate that sumoy-
lation promotes the localization of p53 to the cytoplasm (Carter 
et al., 2007). The role of C-terminal neddylation is interesting 
but not well defined. Mdm2-mediated neddylation of K370, 
K372, and K373 (Xirodimas et al., 2004) and FBXO11-mediated 
neddylation of K320 and K321 (Abida et al., 2007) appear to 
inhibit p53-mediated transcriptional activation. It remains to be 
determined under what circumstances methylation, sumoyla-
tion, and neddylation are required for p53 activation in vivo.
Regulation of p53 by the ASPP Family, 53BP1, and 
Other Cofactors
There are a number of proteins that affect p53 activity through 
their selective interaction with the tumor suppressor. The ASPP 
(ankyrin-repeat-, SH3-domain- and proline-rich-region-con-
taining proteins) family specifically affects the p53-mediated 
apoptotic response (Trigiante and Lu, 2006). The ASPP family 
consists of two proapoptotic mediators, ASPP1 and ASPP2, 
and the antiapoptotic mediator iASSP. ASPP1 and ASPP2 
enhance the proapoptotic function of p53 by selectively pro-
moting the binding of p53 to proapoptotic gene targets such as 
BAX, PUMA, and PIG3 (Samuels-Lev et al., 2001). Conversely, 
iASSP prevents the transcriptional activity of p53 bound to 
proapoptotic promoters (Bergamaschi et al., 2003). However, 
the exact mechanism underlying the promoter specificity of 
ASPP1, ASPP2, and iASSP is still unknown. Interestingly, the 
expression levels of ASPP1/ASPP2 and iASSP correlate with 
cellular sensitivity or resistance to apoptosis. Due to their spe-
cific regulation of the p53 response, targeting the ASPP family 
may have therapeutic potential.
53BP1 binds p53 and mediates promoter specificity by a yet 
unknown mechanism (Iwabuchi et al., 1994). It was originally 
identified together with 53BP2, which was later shown to be 
a truncated N-terminal splice form of ASPP2 and has recently 
been shown to be a coactivator of p53 mediated proliferation 
arrest (Brummelkamp et al., 2006). In addition to its role in the 
regulation of p53, it also has an important function in DNA repair. 
The fact that 53BP1 is involved in both DNA damage repair and 
p53-induced cell cycle arrest suggests that 53BP1 could con-
tribute to the coordination of these responses. With an ever 
growing number of p53-interacting partners being identified, 
such as HZF, APAK, and hCAS/CSE1L (Das et al., 2007; Tanaka 
et al., 2007; Tian et al., 2009), it will be increasingly important to 
characterize cofactors that affect promoter specificity of p53. 
Are there specific cofactors and combinations of cofactors 616 Cell 137, May 15, 2009 ©2009 Elsevier Inc.that regulate specific subsets of target genes? Identifying the 
specific targets affected by an interaction between p53 and its 
cofactors remains critical for advancing our understanding of 
the p53 response in vivo.
Lessons from the Classical Models for p53 Activation
In broad terms, the traditional model for stress-induced p53 
activation consists of a p53 stabilization step that is followed 
by an intricate regulatory network to induce DNA binding and 
transcriptional activation of p53 target genes (Figure 2). The 
stress signal leads to p53 stabilization, primarily via the release 
of p53 from its interaction with Mdm2. Phosphorylation of p53 
inhibits its interaction with Mdm2 and thereby prevents Mdm2-
mediated ubiquitination and the resulting proteasomal degra-
dation of p53. Once stabilized, p53 has been thought to be 
activated by further posttranslational modifications, leading to 
increased binding of p53 to DNA at p53-specific promoters. 
After the binding to specific high- or low-affinity promoter sites, 
p53 would then act as a transcription factor to regulate the 
expression of its target genes, at least in part via the recruit-
ment of coactivators and corepressors.
This classic model of stabilization and activation continues 
to provide an explanation for many modes of p53 regulation, 
especially via posttranslational modifications as observed in 
in vitro biochemical and in tissue culture systems. However, 
recent results from genetic studies introducing point mutations 
in p53 (Toledo and Wahl, 2006) and observations demonstrat-
ing the importance of specific modifications (Tang et al., 2008) 
reveal aspects of p53 regulation that may not be sufficiently 
explained by the classic model. A refined and extended model 
is needed to adequately explain our current understanding of 
p53 activation in vivo.
In vitro and cell culture studies establish that phosphorylation 
is a key event in both p53 stabilization and regulation of DNA 
binding (Appella and Anderson, 2001; Hupp et al., 1992). How-
ever, as discussed above, point mutant knockin approaches 
have shown that the dramatic effects observed in vitro are only 
partially recapitulated in cells and tissues from knockin ani-
mals. These observations point toward a regulatory system for 
p53 in vivo in which individual phosphorylation events may be 
somewhat redundant, yet by no means insignificant. It is very 
likely that the loss of phosphorylation at a particular site can 
be compensated by phosphorylation at different sites, or by 
other types of modifications such as acetylation. Various types 
of stress and different tissues may require different modes for 
p53 regulation. Regulatory redundancy among posttransla-
tional modifications may ensure that p53 is regulated appropri-
ately in response to different stress stimuli and intensities, as 
well as with the required tissue specificity.
A number of key observations suggest that p53 may be 
active in the absence of further activation by stress stimuli. 
As discussed above, both Mdm2 and MdmX knockout mice 
are embryonic lethal, and the rescue of this phenotype by loss 
of p53 indicates that p53 is responsible for the early embry-
onic lethality (Iwakuma and Lozano, 2007; Marine et al., 2006; 
Wahl, 2006). The severity of the phenotypes of the Mdm2 and 
MdmX knockout mice suggests that p53 has significant activ-
ity. Given the early embryonic lethality, it may be impossible to 
Figure 4. Refined Model for p53 Activation
Promoter-specific p53 activation in vivo consists 
of three key steps: (1) p53 stabilization, (2) antire-
pression, and (3) promoter-specific activation.
(1) Stress-induced p53 stabilization occurs through 
many different mechanisms, many of which act by 
affecting the ability of Mdm2 to ubiquitinate p53.
(2) Antirepression describes the release of p53 
from the repression mediated by Mdm2 and 
MdmX. This step requires the acetylation of p53 at 
key lysine residues and facilitates the activation of 
specific subsets of p53 targets. Phosphorylation 
of p53 or treatment with the small molecule Nut-
lin-3 may have similar effects on antirepression.
(3) For full activation of specific promoters, p53 
recruits and interacts with numerous cofactors. 
These act by modifying p53, the surrounding his-
tones, or other transcription factors. Regulating 
the activation of specific groups of p53 targets for 
apoptosis, senescence, cell cycle control, DNA re-
pair, autophagy, metabolism, or aging may require 
exact combinations of cofactors and posttransla-
tional modifications.
Abbreviations: Ac, acetylation; P, phosphorylation; 
Me, methylation; N8, neddylation; S, sumoylation.address whether additional modifications may be required for 
the activation of p53. Instead of further p53 activation via mod-
ifications, the loss of the repressors Mdm2 and MdmX may 
be sufficient to elevate p53 function, which results in embry-
onic lethality. This model is supported by data demonstrating 
that loss of the p53 interaction with either Mdm2 or MdmX, is 
essential for the activation of cell cycle-specific target genes 
(Tang et al., 2008). Interestingly, p53 is spontaneously active in 
tissues lacking mdm2, which leads to p53-dependent patholo-
gies in radiosensitive tissues (Ringshausen et al., 2006). This 
study also demonstrates that this activity of p53 occurs in the 
absence of further posttranslational modifications. The notion 
that p53 does not absolutely require activating modifications 
is supported by results obtained from purified in vitro systems 
(An et al., 2004; Espinosa and Emerson, 2001; Gu et al., 1999). 
These studies raise a fundamental question: what is the main 
purpose of p53 modification during the stress response? Why 
is p53 modification required for some biological settings but 
not others?
p53 Regulation by Antirepression
In light of the studies discussed above, it appears that p53 
activation in vivo requires not only stabilization and activa-
tion by posttranslational modifications, but also release from 
a repressed state. Including this step of antirepression in a 
refined model of p53 activation may provide a more accurate 
way to explain p53 activation in vivo (Figure 4). Both in vitro 
and genetic data indicate that p53 is intrinsically active, yet is 
repressed by its key negative regulators, Mdm2 and MdmX. 
By starting with the view that p53 is intrinsically active, we may 
be able to explain differences observed between in vitro and 
in vivo experiments by the absence or aberrant activity of spe-
cific cofactors or modifications. Interestingly, knockin animals 
that carry the p53QS mutation are embryonic lethal even though 
p53QS retains the ability to bind DNA (Johnson et al., 2005). However, p53QS loses its ability to interact with both Mdm2 and 
MdmX, which may contribute to the embryonic lethality similar 
to that observed in Mdm2 null mice. p53QS has deficiencies 
in transactivation, yet retains the ability to activate some tar-
gets. This may be a consequence of very high levels of p53QS 
because of loss of the interaction with Mdm2. These findings 
further support the concept that p53 is constitutively active 
but continuously repressed. In order to observe the role anti-
repression plays in p53 regulation, both positive and negative 
regulators, as well as p53, need to be present at near physi-
ological levels.
Overexpression of positive or negative regulators of p53 could 
mask the effect of antirepression in vivo. This may explain why in 
vitro experiments using unacetylated p53 show unexpected tran-
scriptional activity in purified systems (An et al., 2004; Espinosa 
and Emerson, 2001), as negative regulators Mdm2 and MdmX 
were not present. This could also explain why overexpression of 
the various kinases that inhibit the p53-Mdm2 interaction lead to 
a masking of this effect. It will be very interesting to determine to 
what extent p53 phosphorylation and p53 acetylation contrib-
ute to the stabilization and activation of p53 by synergistically 
acting to inhibit the binding of p53 to its negative regulators. 
Another intriguing question that arises from the interaction of 
p53 with Mdm2 and MdmX on gene promoters is whether p53 
can be ubiquitinated by Mdm2 while bound to DNA and what 
role phosphorylation may play in regulating the p53 interaction 
with Mdm2 and MdmX when p53 is bound to DNA. Although the 
N-terminus of p53 was originally thought to be the predominant 
site of the interaction with Mdm2, both the DNA-binding domain 
(Wallace et al., 2006; Kulikov et al., 2006; Tang et al., 2008; Yu et 
al., 2006) and the C-terminal domain (Tang et al., 2008) interact 
with Mdm2. The presence of multiple Mdm2 binding sites in p53 
may suggest that there is an interplay between posttranslational 
modifications that activate p53 by stabilization and that release 
it from repression.Cell 137, May 15, 2009 ©2009 Elsevier Inc. 617
It is conceivable that antirepression may have varying degrees 
of significance in vivo, depending on the relative responsive-
ness of different p53 promoters. Whereas antirepression may 
be sufficient for the activation of p53 targets that are highly 
responsive, such as those that block cell cycle progression, 
antirepression alone may be insufficient to induce apoptosis, 
which would require additional p53 posttranslational modifi-
cations. In this proposed mechanism, a stress signal would 
initially result in reversible cell cycle arrest, and the more 
dramatic and irreversible apoptotic response would require 
additional stimulation. Such regulatory specificity may explain 
results showing that the small molecule Nutlin-3 acts primarily 
to activate cell cycle control genes, whereas the transactiva-
tion of proapoptotic p53 targets is comparatively weak (Tovar 
et al., 2006; Vassilev et al., 2004). Inhibition of the p53-Mdm2 
interaction leading to p53 stabilization and removal of Mdm2-
mediated repression at the promoter may be sufficient to acti-
vate cell cycle arrest upon Nutlin-3 treatment, although certain 
cofactors may be still needed (Brummelkamp et al., 2006). In 
contrast, the induction of apoptotic p53 targets may require 
additional signals and posttranslational modifications of p53. 
This type of differential regulation of specific targets and the 
concomitant importance of different cofactors reacting to vary-
ing stress signals may explain why phenotypes from knockin 
mice with specific point mutations are modest compared to 
in vitro results. In a given knockin animal, cells from different 
tissues may respond to specific stress signals via a multitude 
of pathways to activate p53. Although particular aspects of the 
response may be inhibited by the loss of a specific modifica-
tion site, overall stress responses may remain intact if p53 can 
still be released from repression and other modifications aug-
ment p53 activation to trigger appropriate responses.
Concluding Remarks
Here, based on the latest advances, we have proposed that 
p53 activation in vivo consists of three major steps: (1) p53 
stabilization, (2) antirepression, and (3) promoter-specific acti-
vation (Figure 4). In this refinement of the current model, p53 
stabilization involves multiple layers of Mdm2 regulation; anti-
repression, which is mediated by p53 acetylation and probably 
phosphorylation; and promoter-specific activation of p53 tar-
get genes involving additional posttranslational modifications 
and cofactor recruitment.
Although the previous 30 years of p53 research have led to 
an incredibly detailed understanding of the biology of p53, a 
number of key questions in the study of p53 activation con-
tinually reappear in a new form. Are there unified mechanisms 
that control p53 stabilization in vivo? Do different tissues and 
stress factors use different pathways for the stabilization of 
p53? How does the cell coordinate the status of DNA repair 
and the levels of p53 activation? What is the in vivo significance 
of ATM- and ATR-mediated phosphorylation in p53 activation? 
Are the activities of HATs such as CBP/p300 and Tip60/MOF 
regulated upon stress? How are the many different types of 
lysine modification of the C-terminal domain coordinated? 
How many targets of p53 are repressed by the presence of 
Mdm2 and MdmX? How does Mdm2 or MdmX repress tran-
scriptional activation on DNA? Do promoters for specific p53 618 Cell 137, May 15, 2009 ©2009 Elsevier Inc.responses have similar modes of regulation? For example, are 
all proapoptotic target genes under the control of one or more 
specific regulatory mechanisms that are different from mecha-
nisms regulating senescence, autophagy, or metabolic tar-
gets? Is there any specific target gene of p53 directly involved 
in the control of aging or antiaging processes? As in the past, 
answers to such questions will mean that models for the acti-
vation of p53 will need to continually evolve.
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